Translating genomic discoveries to the clinic in pediatric oncology

Current Opinion in Pediatrics

Volumn 27, Issue 1, 2015, Pages 34-43

  Bender, Julia Glade ^a   Verma, Anupam ^b   Schiffman, Joshua D ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

genomic alterations; incidental findings; pediatric cancer; personalized medicine; precision oncology; targeted therapy

Indexed keywords

ABELSON KINASE; ACVR1 PROTEIN; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BCR ABL PROTEIN; BCR ABL1 PROTEIN; COHESIN; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DASATINIB; EVEROLIMUS; FBXW7 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLT3 LIGAND; IKZF1 PROTEIN; IMATINIB; K RAS PROTEIN; MYC PROTEIN; MYCN PROTEIN; NOTCH RECEPTOR; PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TEMSIROLIMUS; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CANCER STAGING; CHILDHOOD CANCER; CRANIOPHARYNGIOMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DNA METHYLATION; EPENDYMOMA; EWING SARCOMA; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GERMLINE MUTATION; GLIOMA; HISTONE MODIFICATION; HUMAN; INCIDENTAL FINDING; INDEL MUTATION; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; MEDULLOBLASTOMA; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; T CELL LEUKEMIA; TREATMENT RESPONSE; CHILD; CLINICAL TRIAL (TOPIC); GENETICS; INFANT; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ONCOLOGY; PRESCHOOL CHILD; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENTAL FINDINGS; INDIVIDUALIZED MEDICINE; INFANT; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84921567971     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000172     Document Type: Review

References (103)

1. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31:1806-1814
2. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol 2013; 31:1825-1833
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001; 344:783-792
4. OBrien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemur-afenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
8. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383
9. Tsimberidou A-M, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase Iprogram at MD Anderson: validation and landmark analyses. Clin Cancer Res 2014; 20:4827-4836
10. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-421
11. Huether R, Dong L, Chen X, et al. The landscape of somatic mutations in epigenetic regulators across 1, 000 paediatric cancer genomes. Nat Commun 2014; 5:3630
12. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004; 104:2655-2660
13. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharma-cokinetic study of dasatinib: a report from the Children's Oncology Group phase I consortium. J Clin Oncol 2011; 29:839-844
14. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005; 23:6172-6180
15. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharma-cokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008; 26:4921-4927
16. Fouladi M, Stewart CF, Blaney SM, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28:4221-4227
17. Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010; 28:4762-4768
18. DuBois SG, Shusterman S, Reid JM, et al. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol 2012; 69:1021-1027
19. Dubois SG, Shusterman S, Ingle AM, et al. Phase I and pharmaco-kinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology group study. Clin Cancer Res 2011; 17: 5113-5122
20. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group phase I consortium report. Clin Cancer Res 2012; 18: 6011-6022
21. Glade Bender JL, Lee A, Reid JM, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a Children's Oncology group phase I consortium report. J Clin Oncol 2013; 31:3034-3043
22. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14:472-480
23. Tasian SK, Loh ML, Rabin KR, et al. A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase I consortium study (ADVL1011). J Clin Oncol 2014; 32 (Suppl):5s. [abstract 10019
24. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25: 4806-4812
25. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011; 29:2933-2940
26. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharma-cokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3629
27. Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 20132013; 19:6305-6312
28. Ebb D, Meyers P, Grier H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2545-2551
29. Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators consortium. J Clin Oncol 2009; 27:5102-5108
30. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharma-cokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol 2008; 26:399-405
31. Advani RH, Shustov AR, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update. ASH Annual Meeting Abstracts 2011;118:443
32. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodg-kin lymphoma. ASH Annual Meeting Abstracts 2010;116:283
33. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2009; 27: 5175-5181
34. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014; 28:1467-1471
35. Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122:2983-2988
36. Downing JR, Wilson RK, Zhang J, et al. The Pediatric Cancer Genome Project. Nat Genet 2012; 44:619-622
37. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29:3293-3300
38. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012; 120:1165-1174
39. Van Der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122:2622-2629
40. Iacobucci I, Iraci N, Messina M, et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 2012; 7:e40934
41. Feldhahn N, Klein F, Mooster JL, et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 2005; 201:1837-1852
42. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005-1015
43. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23:307-318
44. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10:147-156
45. Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL. Br J Haematol 2014; 166:421-424
46. Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J 2012; 18:450-456
47. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14:e370-e379
48. Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014; 46:451-456
49. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 2014; 46:462-466
50. Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 2014; 46:457-461
51. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric nonbrainstem high-grade glioma. Nat Genet 2014; 46:444-450
52. Zadeh G, Aldape K. ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. Nat Genet 2014; 46:421-422
53. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45:602-612
54. Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45:927-932
55. Turcan S, Chan TA. MAPping the genomic landscape of low-grade pediatric gliomas. Nat Genet 2013; 45:847-849
56. Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014; 506:445-450
57. Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 2014; 506:451-455
58. Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46:161-165
59. Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol 2014; 27:689-696
60. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (Berl) 2012; 123:465-472
61. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:43-48
62. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature 2012; 488:49-56
63. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012; 148:59-71
64. Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014; 32:886-896
65. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927-2935
66. Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (Berl) 2013; 126:917-929
67. Schwalbe EC, Williamson D, Lindsey JC, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (Berl) 2013; 125:359-371
68. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971-974
69. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455:975-978
70. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455:967-970
71. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930-935
72. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45:279-284
73. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121-1124
74. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013; 3:308-323
75. Wyce A, Ganji G, Smitheman KN, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One 2013; 8:e72967
76. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014; 4:216-231
77. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30:1670-1677
78. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children's Oncology Group report. Pediatr Blood Cancer 2013; 60:1411-1417
79. Brohl AS, Solomon DA, Chang W, et al. The genomic landscapeofthe Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 2014; 10:e1004475
80. Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014; 4:1326-1341
81. Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014; 4:1342-1353
82. McLellan JL, ONeil NJ, Barrett I, et al. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 2012; 8:e1002574
83. ONeil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends Genet 2013; 29:290-297
84. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023-1031
85. Hawryluk MJ, Wang K, Chmielecki J, et al. Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: the Foundation Medicine pediatric experience. J Clin Oncol 2014; 32 (Suppl):5s. [abstract 10035
86. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4:e7887
87. Janeway KA, DuBois SG, Glade Bender JL, et al. Multicenter study assessing tumor molecular profiles in advanced pediatric solid tumors. J Clin Oncol 2014; 32 (Suppl):5s. [abstract 10011
88. Parsons DW, Roy A, Monzon FA, et al. What's in an exome?. Diversity of diagnostic and incidental findings revealed by clinical tumor and germline sequencing of 100 children with solid tumors. J Clin Oncol 2014; 32 (Suppl):5s. [abstract 10012
89. Church A, Grimmett L, Kim A, et al. Analysis of somatic copy number alterations in pediatric solid tumors using array comparative genomic hybridization. J Clin Oncol 2014; 32 (Suppl):5s. [abstract 1538
90. Jiang Y, Subbiah V, Janku F, et al. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One 2014; 9:e93676
91. Knapke S, Nagarajan R, Correll J, et al. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer 2012; 58:85-89
92. Knapke S, Zelley K, Nichols KE, et al. Identification, management, and evaluation of children with cancer-predisposition syndromes. Am Soc Clin Oncol Educ Book 2012; 576-584
93. Schiffman JD. Hereditary cancer syndromes: if you look, you will find them. Pediatr Blood Cancer 2012; 58:5-6
94. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 5:565-574
95. Vayena E, Tasioulas J. Genetic incidental findings: autonomy regained?. Genet Med 2013; 15:868-870
96. McCormick JB, Sharp RR, Farrugia G, et al. Genomic medicine and incidental findings: balancing actionability and patient autonomy. Mayo Clin Proc 2014; 89:718-721
97. Ross LF, Rothstein MA, Clayton EW. Mandatory extended searches in all genome sequencing: incidental findings, patient autonomy, and shared decision making. JAMA 2013; 310:367-368
98. Townsend A, Adam S, Birch PH, Friedman JM. Paternalism and the ACMG recommendations on genomic incidental findings: patients seen but not heard. Genet Med 2013; 15:751-752
99. Burke W, Matheny Antommaria AH, Bennett R, et al. Recommendations for returning genomic incidental findings?. We need to talk Genet Med 2013; 15:854-859
100. Jarvik GP, Amendola LM, Berg JS, et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 2014; 94:818-826
101. Parsons DW, Roy A, Plon SE, et al. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol 2014; 32:2203-2205
102. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-892
103. Schleiermacher G, Javanmardi N, Bernard V, et al. Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol 2014; 32:2727-2734